InvestorsHub Logo
Followers 32
Posts 19870
Boards Moderated 0
Alias Born 07/10/2015

Re: boston745 post# 40716

Saturday, 03/30/2024 11:42:38 AM

Saturday, March 30, 2024 11:42:38 AM

Post# of 40972
Sintx ties to Zimmer were purposefully withheld from Sintx's IPO paperwork in 2013. Look at the summary about who Dr Link is for the 2007 IPO and compare that to the disclosure in the 2013 IPO paperwork. You will see that in the 2013 paperwork it was purposefully withheld that Zimmer acquired Centerpulse when Dr. Link was CEO of Centerpulse. Even how Centerpulse is described is vastly different between 2007/2013 paperwork.
Any investigation is unfortunately going to need to start right here as i suspect this is a breach of disclosure required. Most likely a small infraction. There is enough evidence to suggest intent.

Dr. Max Link, PHD (Chairman 2003-2014)

Max Link, Ph.D. has served as the Chairman of our board of directors since October 2003. Dr. Link served as Chairman of the Board and Chief Executive Officer of Centerpulse AG, the largest orthopedics company in Europe, from March 2002 until October 2003, when Centerpulse was acquired by Zimmer Holdings, Inc. Prior to joining Centerpulse,



Max E. Link, Ph.D. has served as the chairman of our board of directors since October 2003. Dr. Link was chairman of the board of directors and Chief Executive Officer of Centerpulse AG, a medical implant company from March 2002 to October 2003. Prior to joining Centerpulse,



Next if you look at the summary of Dr Aaron Hofmann, cofounder of Sintx and a member of the board of Sintx when Sintx first tried to IPO, you'll see inclusion of him being a surgeon designer for Zimmer in the 2007 IPO paperwork. Yet the information about Dr Sonny Bal, also a board member, the fact that hes a surgeon designer for Zimmer in the 2013 IPO paperwork is not disclosed.

Disclosure about Dr. Hofmann, MD in 2007 IPO paperwork

Aaron A. Hofmann, M.D. is our co-founder and has been a member of our board of directors since 1996. Dr. Hofmann is a nationally and internationally recognized orthopedic surgeon, known for his accomplishments in developing total hip and knee replacement systems, innovative surgical approaches in hip and knee surgery and basic research on human bone dynamics. Dr. Hofmann holds 14 patents, many of which are directed at inventions involving hip and knee implants. Since 2003, Dr. Hofmann has been a design surgeon for Zimmer Holdings, Inc., the largest orthopedics company in the world. Dr. Hofmann, working with a team of orthopedic surgeons, helped design Zimmer’s new gender knee specifically designed for women.



Disclosure of Dr Bal, MD in the 2013 IPO paperwork:

B. Sonny Bal, M.D. has served on our board of directors since February 2012. Dr. Bal is Professor & Chief of Adult Reconstruction at the University of Missouri, Columbia, specializing in hip and knee replacement surgery. He also is an Adjunct Professor of Material Sciences at the University of Missouri at Rolla. Dr. Bal is a member of the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons. Dr. Bal received his M.D. degree from Cornell University and an M.B.A. from Northwestern University, and a J.D. from the University of Missouri. Dr. Bal is a licensed attorney and co-founder of the Bal Brenner law firm in North Carolina.

We believe that Dr. Bal’s expertise in orthopedic surgery and his specialty in hip and knee replacement surgery qualifies him to serve on our board of directors.



Per Dr Bals resume:

Designer Surgeon Panel, Zimmer Inc., Warsaw, Indiana, 2002 to present.

Total Joint Reconstruction Clinical Advisory Panel, Amedica Inc., Salt Lake City, UT, 2005 to present.



1. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 73
2. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 89
3. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 74
4. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 90
5. https://web.archive.org/web/20240316192627/https://hipandknee.com/wp-content/uploads/2014/04/Dr.-Bal-CV.pdf

Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News